Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
IceCure Medical's Cryogen Pump patent application approved by USPTO » 08:05
01/23/23
01/23
08:05
01/23/23
08:05
ICCM

IceCure Medical

$1.26 /

-0.045 (-3.45%)

IceCure Medical has…

IceCure Medical has received a Notice of Allowance from the USPTO for its patent application titled "Cryogen Pump". The patent will be in effect until February 2040 and was recently granted in the EU and allowed in Japan. IceCure's cryogenic pump is submersible in liquid nitrogen, works in a closed circuit, enables temperature control of the cryoprobe, improves the cooling rate during a procedure, and is designed to be used for multiple procedures or longer duration procedures without the need to refill liquid nitrogen.

ShowHide Related Items >><<
ICCM IceCure Medical
$1.26 /

-0.045 (-3.45%)

ICCM IceCure Medical
$1.26 /

-0.045 (-3.45%)

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
ICCM IceCure Medical
$1.26 /

-0.045 (-3.45%)

Over a week ago
Hot Stocks
IceCure Medical receives notice of allowance in Japan for Cryogen Pump patent » 08:10
01/18/23
01/18
08:10
01/18/23
08:10
ICCM

IceCure Medical

$1.24 /

+0.02 (+1.64%)

IceCure Medical announced…

IceCure Medical announced it has received a Notice of Allowance from the Japan Patent Office, or JPO, for IceCure's patent application titled "Cryogen Pump". The patent will be in effect until 2041. A patent for this invention has been issued in the European Union and is pending in other major markets, including the U.S. IceCure's novel cryogenic pump is submersible in liquid nitrogen, works in a closed circuit, improves the cooling rate during a procedure, and is designed to be used for multiple procedures or longer duration procedures without the need to refill liquid nitrogen. Moreover, this pump enables temperature control of the cryoprobe, as well as the use of a wider range of cryoprobes and catheters.

ShowHide Related Items >><<
ICCM IceCure Medical
$1.24 /

+0.02 (+1.64%)

ICCM IceCure Medical
$1.24 /

+0.02 (+1.64%)

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
ICCM IceCure Medical
$1.24 /

+0.02 (+1.64%)

Over a month ago
Syndicate
IceCure Medical prices at-the-market offering at $1.65 per share » 09:26
12/21/22
12/21
09:26
12/21/22
09:26
ICCM

IceCure Medical

$2.72 /

+1.8 (+195.65%)

IceCure Medical…

IceCure Medical "announced the pricing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares priced at-the-market under Nasdaq rules at a price to the public of $1.65 per share. The gross proceeds of the offering to the Company are expected to be approximately $14.5 million, before deducting placement agent fees, commissions, and other estimated offering expenses."

ShowHide Related Items >><<
ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

On The Fly
Fly Intel: After-Hours Movers » 17:44
12/20/22
12/20
17:44
12/20/22
17:44
CAMP

CalAmp

$3.45 /

+0.0402 (+1.18%)

, NKE

Nike

$103.23 /

+0.215 (+0.21%)

, FDX

FedEx

$164.34 /

-4.46 (-2.64%)

, CVGW

Calavo Growers

$33.81 /

-0.335 (-0.98%)

, AIR

AAR Corp.

$45.21 /

+0.34 (+0.76%)

, ICCM

IceCure Medical

$2.72 /

+1.8 (+195.65%)

, PEB

Pebblebrook Hotel

$14.44 /

-0.165 (-1.13%)

, GLDD

Great Lakes Dredge

$6.44 /

-0.06 (-0.92%)

Check out this evening's…

ShowHide Related Items >><<
PEB Pebblebrook Hotel
$14.44 /

-0.165 (-1.13%)

NKE Nike
$103.23 /

+0.215 (+0.21%)

ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

GLDD Great Lakes Dredge
$6.44 /

-0.06 (-0.92%)

FDX FedEx
$164.34 /

-4.46 (-2.64%)

CVGW Calavo Growers
$33.81 /

-0.335 (-0.98%)

CAMP CalAmp
$3.45 /

+0.0402 (+1.18%)

AIR AAR Corp.
$45.21 /

+0.34 (+0.76%)

CAMP CalAmp
$3.45 /

+0.0402 (+1.18%)

08/16/22 Craig-Hallum
Craig-Hallum upgrades CalAmp to Buy, raises price target to $10
08/16/22 Craig-Hallum
CalAmp upgraded to Buy from Hold at Craig-Hallum
06/24/22 Goldman Sachs
Goldman Sachs cuts CalAmp EBITDA estimates on lower margin forecasts
03/25/22 Jefferies
CalAmp price target lowered to $13 from $16 at Jefferies
NKE Nike
$103.23 /

+0.215 (+0.21%)

12/16/22 Cowen
Nike price target raised to $122 from $118 at Cowen
12/16/22 Credit Suisse
Nike price target raised to $122 from $110 at Credit Suisse
12/15/22 Deutsche Bank
Nike price target raised to $126 from $99 at Deutsche Bank
12/14/22 BofA
Nike price target raised to $112 from $100 at BofA
FDX FedEx
$164.34 /

-4.46 (-2.64%)

12/19/22 Evercore ISI
FedEx price target lowered to $202 from $225 at Evercore ISI
12/15/22 Baird
FedEx price target lowered to $230 from $240 at Baird
12/13/22 Wells Fargo
FedEx price target raised to $185 from $160 at Wells Fargo
12/08/22 JPMorgan
FedEx price target lowered to $184 from $192 at JPMorgan
CVGW Calavo Growers
$33.81 /

-0.335 (-0.98%)

09/02/22 Lake Street
Calavo Growers headwind sources in Q3 unlikely to persist, says Lake Street
06/03/22 Lake Street
Calavo Q2 offered 'most significant signs of a turnaround yet,' says Lake Street
12/21/21 Lake Street
Calavo Growers results 'should provide comfort,' says Lake Street
AIR AAR Corp.
$45.21 /

+0.34 (+0.76%)

09/23/22 Truist
AAR Corp. price target lowered to $48 from $54 at Truist
07/19/22 Truist
AAR Corp. price target lowered to $54 from $58 at Truist
03/23/22 RBC Capital
AAR Corp. price target raised to $56 from $50 at RBC Capital
03/23/22 Truist
AAR Corp. price target raised to $58 from $53 at Truist
ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
PEB Pebblebrook Hotel
$14.44 /

-0.165 (-1.13%)

12/09/22 Raymond James
Pebblebrook Hotel downgraded to Market Perform from Outperform at Raymond James
12/09/22 Raymond James
Pebblebrook Hotel downgraded to Market Perform from Outperform at Raymond James
12/05/22 Morgan Stanley
Pebblebrook Hotel initiated with an Underweight at Morgan Stanley
12/02/22 BMO Capital
Pebblebrook Hotel downgraded to Market Perform from Outperform at BMO Capital
GLDD Great Lakes Dredge
$6.44 /

-0.06 (-0.92%)

PEB Pebblebrook Hotel
$14.44 /

-0.165 (-1.13%)

NKE Nike
$103.23 /

+0.215 (+0.21%)

GLDD Great Lakes Dredge
$6.44 /

-0.06 (-0.92%)

FDX FedEx
$164.34 /

-4.46 (-2.64%)

CVGW Calavo Growers
$33.81 /

-0.335 (-0.98%)

CAMP CalAmp
$3.45 /

+0.0402 (+1.18%)

AIR AAR Corp.
$45.21 /

+0.34 (+0.76%)

NKE Nike
$103.23 /

+0.215 (+0.21%)

FDX FedEx
$164.34 /

-4.46 (-2.64%)

PEB Pebblebrook Hotel
$14.44 /

-0.165 (-1.13%)

NKE Nike
$103.23 /

+0.215 (+0.21%)

ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

FDX FedEx
$164.34 /

-4.46 (-2.64%)

CAMP CalAmp
$3.45 /

+0.0402 (+1.18%)

AIR AAR Corp.
$45.21 /

+0.34 (+0.76%)

NKE Nike
$103.23 /

+0.215 (+0.21%)

FDX FedEx
$164.34 /

-4.46 (-2.64%)

Hot Stocks
ICCM Stock trading halted, news pending  16:55
12/20/22
12/20
16:55
12/20/22
16:55
ICCM

IceCure Medical

$2.72 /

+1.8 (+195.65%)

 
ShowHide Related Items >><<
ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
ICCM IceCure Medical
$2.72 /

+1.8 (+195.65%)

Syndicate
IceCure Medical announces ordinary shares offering, no amount given » 16:02
12/20/22
12/20
16:02
12/20/22
16:02
ICCM

IceCure Medical

$3.20 /

+2.28 (+247.83%)

IceCure Medical Ltd.…

IceCure Medical Ltd. announced the commencement of a proposed public offering of its ordinary shares. The company intends to use the net proceeds from the offering to fund the development of its next generation single Probe and MultiSense systems, collecting clinical data and adding regulatory approvals in new territories and indications, business development, marketing and selling activities as well as for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as lead placement agent for the offering on a best efforts basis. Brookline Capital Markets, a division of Arcadia Securities, is acting as a co-placement agent for the offering.

ShowHide Related Items >><<
ICCM IceCure Medical
$3.20 /

+2.28 (+247.83%)

ICCM IceCure Medical
$3.20 /

+2.28 (+247.83%)

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
ICCM IceCure Medical
$3.20 /

+2.28 (+247.83%)

On The Fly
Fly Intel: After-Hours Movers » 18:24
12/19/22
12/19
18:24
12/19/22
18:24
ICCM

IceCure Medical

/

+

, TRDA

Entrada Therapeutics

$20.15 /

-1.11 (-5.22%)

, RCUS

Arcus Biosciences

$30.52 /

-0.385 (-1.25%)

, TERN

Terns Pharmaceuticals

$8.93 /

+2.15 (+31.71%)

Check out this evening's…

ShowHide Related Items >><<
TRDA Entrada Therapeutics
$20.15 /

-1.11 (-5.22%)

TERN Terns Pharmaceuticals
$8.93 /

+2.15 (+31.71%)

RCUS Arcus Biosciences
$30.52 /

-0.385 (-1.25%)

ICCM IceCure Medical
/

+

ICCM IceCure Medical
/

+

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
TRDA Entrada Therapeutics
$20.15 /

-1.11 (-5.22%)

RCUS Arcus Biosciences
$30.52 /

-0.385 (-1.25%)

11/23/22 Citi
Arcus Biosciences price target lowered to $37 from $40 at Citi
11/18/22 BofA
Arcus Biosciences initiated with a Neutral at BofA amid near-term caution
11/18/22 BofA
Arcus Biosciences initiated with a Neutral at BofA
10/11/22 Morgan Stanley
Arcus Biosciences initiated with an Overweight at Morgan Stanley
TERN Terns Pharmaceuticals
$8.93 /

+2.15 (+31.71%)

09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
03/23/22 JPMorgan
Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
TRDA Entrada Therapeutics
$20.15 /

-1.11 (-5.22%)

TERN Terns Pharmaceuticals
$8.93 /

+2.15 (+31.71%)

RCUS Arcus Biosciences
$30.52 /

-0.385 (-1.25%)

  • 21
    Dec
RCUS Arcus Biosciences
$30.52 /

-0.385 (-1.25%)

Hot Stocks
IceCure Medical reports interim results from the ICESECRET study » 16:07
12/19/22
12/19
16:07
12/19/22
16:07
ICCM

IceCure Medical

/

+

IceCure Medical announced…

IceCure Medical announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Data were presented on December 14, 2022 at the Urological Association Conference in Eilat, Israel. The presentation titled "Renal Mass Cryoablation - Interim Analysis ICESECRET Study" was delivered by Dr. Nasir Said of Bnai Zion Medical Center. According to the presentation, out of the 115 patients enrolled, 107 patients returned for follow-up with a mean duration of 22.8 months and a range 12-60 months. In a subgroup of patients with no previous history of kidney cancer on the same kidney and a lesion less than or equal to3 cm, an 89.5% recurrence-free rate was observed at a mean follow-up time of 22.2 months when the procedure protocol was followed. The recurrence-free rate was 85.1% for the 107 patients at a mean follow-up period of 16.5 months. 5 serious adverse events were reported, 4 of which were of mild severity and were treated conservatively and resolved within 1-5 days, with one severe complication of a new onset of ipsilateral hydronephrosis 7 months after the cryoablation procedure that led to nephrectomy. Cryoablation time and hospitalization time were relatively short, up to approximately 25 minutes and 2 days, respectively. The presentation concluded that, based on these interim results, cryoablation is safe and effective for treating renal masses under 5 cm.

ShowHide Related Items >><<
ICCM IceCure Medical
/

+

ICCM IceCure Medical
/

+

10/25/22 Maxim
IceCure Medical initiated with a Buy at Maxim
05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
Over a quarter ago
Initiation
IceCure Medical initiated with a Buy at Maxim » 08:01
10/25/22
10/25
08:01
10/25/22
08:01
ICCM

IceCure Medical

$1.24 /

-0.04 (-3.13%)

Maxim analyst Anthony…

Maxim analyst Anthony Vendetti initiated coverage of IceCure Medical with a Buy rating and $3 price target. The company's flagship ProSense System in the treatment of small benign and malignant tumors offers several advantages over surgical treatment alternatives including a lower cost, less pain, faster procedure times, minimal recovery time, lower infection risk, superior cosmetic results, and the ability to be performed outpatient, without the use of general anesthesia, the analyst tells investors in a research note. Vendetti further cites IceCure's focus on receiving FDA clearance for early-stage breast cancer indications, which he expects to significantly increase its total addressable market, adding that with $17.7M in cash and no debt, the company has sufficient capital to operate into Q3 of next year.

ShowHide Related Items >><<
ICCM IceCure Medical
$1.24 /

-0.04 (-3.13%)

ICCM IceCure Medical
$1.24 /

-0.04 (-3.13%)

05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global
Hot Stocks
IceCure Medical submits filing with FDA for market authorization of Prosense » 08:09
10/19/22
10/19
08:09
10/19/22
08:09
ICCM

IceCure Medical

$1.18 /

-0.08 (-6.35%)

IceCure Medical announced…

IceCure Medical announced it submitted a regulatory filing, a De Novo Classification Request, with the FDA for marketing authorization based on ICE3 clinical trial interim analysis of ProSense for the indication of early-stage low-risk breast cancer in patients who are at high risk to surgery, representing approximately 43,000 women in the U.S. annually. The specific indication filed is based on interim data and is in accordance with discussions IceCure has had with the FDA, which granted ProSense Breakthrough Device Designation, enabling closer communications regarding its regulatory filing. ICE3 is the largest controlled, multicenter clinical trial ever performed in the U.S. for liquid nitrogen-based cryoablation of small, low-risk, early-stage malignant breast tumors. To date, there have been six cases of ipsilateral breast tumor recurrence, or IBTR, out of 194 patients, or 3.09%. The survival-based estimate for the 5-year IBTR is 4.3% with a one-sided 95% confidence level, upper bound of 8.4% for the entire study population. Final ICE3 5-year follow-up data are expected in the first half of 2024, at which time IceCure plans to file with the FDA for a broader indication reflecting the entire study population-early-stage low-risk breast cancer for patients age 60 and over, representing approximately 65,000 women in the U.S. annually.

ShowHide Related Items >><<
ICCM IceCure Medical
$1.18 /

-0.08 (-6.35%)

ICCM IceCure Medical
$1.18 /

-0.08 (-6.35%)

05/19/22 Alliance Global Partners
IceCure price target lowered to $5.75 from $9.50 at Alliance Global
02/02/22 Brookline
IceCure Medical initiated with a Buy at Brookline
01/14/22 Alliance Global Partners
IceCure Medical price target lowered to $9.50 from $14.50 at Alliance Global

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.